Antisense therapy: Current status in prostate cancer and other malignancies

2006 ◽  
pp. 303-316
Author(s):  
Martin Gleave ◽  
Hideake Miyake ◽  
Uwe Zangemeister-Wittke ◽  
Burkhard Jansen
Keyword(s):  
Prostate Cancer ◽  
Current Status ◽  
Antisense Therapy

scholarly journals Prostate Cancer Registries: Current Status and Future Directions

2016 ◽  
Vol 69 (6) ◽  
pp. 998-1012 ◽  
Author(s):  
Giorgio Gandaglia ◽  
Freddie Bray ◽  
Matthew R. Cooperberg ◽  
R. Jeffrey Karnes ◽  
Michael J. Leveridge ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Registries ◽  
Current Status ◽  
Future Directions

scholarly journals Current status of active surveillance in prostate cancer

2016 ◽  
Vol 57 (1) ◽  
pp. 14 ◽  
Author(s):  
Mun Su Chung ◽  
Seung Hwan Lee
Keyword(s):  
Prostate Cancer ◽  
Active Surveillance ◽  
Current Status

scholarly journals The Current Status of Metastatic Castration-Naïve Prostate Cancer Management

2020 ◽  
Vol 18 (1) ◽  
pp. 11-17
Author(s):  
See Min Choi ◽  
Jae Hwi Choi ◽  
Jeong Seok Hwa
Keyword(s):  
Prostate Cancer ◽  
Current Status ◽  
Cancer Management ◽  
Prostate Cancer Management

scholarly journals The management of patients with metastatic prostate cancer during the COVID-19 pandemic

2020 ◽  
Vol 16 (20) ◽  
pp. 1455-1461 ◽  
Author(s):  
Tarek Assi ◽  
Nathalie Ibrahim ◽  
Rita-Maria K Abboud ◽  
Clarisse Kattan ◽  
Elie Rassy ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Immune System ◽  
Androgen Deprivation Therapy ◽  
Serine Proteases ◽  
Metastatic Prostate Cancer ◽  
Current Status ◽  
Patients With Cancer ◽  
Global Pandemic ◽  
A Cell ◽  
Optimal Approach

During the ongoing global pandemic of coronavirus disease 2019 (COVID-19), the benefit of treating patients with cancer must be weighed against the COVID-19 infection risks to patients, staff and society. Prostate cancer is one of the most common cancers among men and raises particular interest during the pandemic as recent reports show that the TMPRSS2 (and other serine proteases), which facilitate the entry, replication and budding of the virion from a cell, can be inhibited using androgen deprivation therapy. Nevertheless, patients with metastatic prostate cancer commonly receive chemotherapy which may compromise their immune system. This paper aims to address the current status of the COVID-19 in patients with cancer overall and suggests an optimal approach to patients with metastatic prostate cancer.

scholarly journals The Use of Ultrasound Imaging in the External Beam Radiotherapy Workflow of Prostate Cancer Patients

2018 ◽  
Vol 2018 ◽  
pp. 1-16 ◽  
Author(s):  
Saskia M. Camps ◽  
Davide Fontanarosa ◽  
Peter H. N. de With ◽  
Frank Verhaegen ◽  
Ben G. L. Vanneste
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Ultrasound Imaging ◽  
Organs At Risk ◽  
External Beam Radiotherapy ◽  
Treatment Options ◽  
Current Status ◽  
Tumor Control ◽  
External Beam ◽  
Image Guided Radiotherapy

External beam radiotherapy (EBRT) is one of the curative treatment options for prostate cancer patients. The aim of this treatment option is to irradiate tumor tissue, while sparing normal tissue as much as possible. Frequent imaging during the course of the treatment (image guided radiotherapy) allows for determination of the location and shape of the prostate (target) and of the organs at risk. This information is used to increase accuracy in radiation dose delivery resulting in better tumor control and lower toxicity. Ultrasound imaging is harmless for the patient, it is cost-effective, and it allows for real-time volumetric organ tracking. For these reasons, it is an ideal technique for image guidance during EBRT workflows. Review papers have been published in which the use of ultrasound imaging in EBRT workflows for different cancer sites (prostate, breast, etc.) was extensively covered. This new review paper aims at providing the readers with an update on the current status for prostate cancer ultrasound guided EBRT treatments.

Sign in / Sign up

Export Citation Format

Share Document